[1]王妮娜,李晓花,陈敏丽,等.肺癌患者血清NSE,SCC,CA125及 CYFRA21-1水平检测在不同病理类型早期诊断和化疗疗效评价中的应用价值[J].现代检验医学杂志,2021,36(01):33-37.[doi:10.3969/j.issn.1671-7414.2021.01.009]
 WANG Ni-na,LI Xiao-hua,CHEN Min-li,et al.Application Value of Serum NSE, SCC, CA125 and CYFRA21-1 in Patients of Lung Cancer for Early Diagnosis and Evaluation of Chemotherapy Efficacy in Patients with Different Pathological Types[J].Journal of Modern Laboratory Medicine,2021,36(01):33-37.[doi:10.3969/j.issn.1671-7414.2021.01.009]
点击复制

肺癌患者血清NSE,SCC,CA125及 CYFRA21-1水平检测在不同病理类型早期诊断和化疗疗效评价中的应用价值()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年01期
页码:
33-37
栏目:
论 著
出版日期:
2021-02-05

文章信息/Info

Title:
Application Value of Serum NSE, SCC, CA125 and CYFRA21-1 in Patients of Lung Cancer for Early Diagnosis and Evaluation of Chemotherapy Efficacy in Patients with Different Pathological Types
文章编号:
1671-7414(2021)01-033-05
作者:
王妮娜李晓花陈敏丽
(宝鸡市中心医院 a.放射治疗科 ; b.肿瘤内科 ,陕西宝鸡 721008)
Author(s):
WANG Ni-na LI Xiao-hua CHEN Min-liet al
(a. Department of Radiotherapy;b. Department of Oncology, Baoji Central Hospital, Shaanxi Baoji 721008, China)
关键词:
神经元特异性烯醇化酶鳞状上皮细胞癌抗原细胞角蛋白 -19片断抗原肺癌病理分型
分类号:
R734.2;R730.43
DOI:
10.3969/j.issn.1671-7414.2021.01.009
文献标志码:
A
摘要:
目的 研究肺癌患者血清神经元特异性烯醇化酶( neuron speci.c enolase,NSE)、鳞状上皮细胞癌抗原( squamous cell carcinoma antigen,SCC)、糖类癌抗原 125(carbohydratte cancer antigen 125,CA125)及细胞角蛋白 -19片断抗原(cytokeratin-19 fragment antigen,CYFRA21-1)检测在不同病理类型早期诊断和化疗疗效评估中的作用。方法 纳入宝鸡市中心医院放射治疗科 78例肺癌患者作为研究对象,采用免疫电化学发光法检测血清 NSE,SCC,CA125及 CYFRA21-1水平,记录病理分型检测结果。比较腺癌、鳞癌及小细胞肺癌( small cell lung cancer,SCLC)不同病理分型患者血清 NSE,SCC,CA125及 CYFRA21-1水平。分析血清 NSE,SCC,CA125及 CYFRA21-1对诊断不同病理分型患者及判断化疗近期疗效的准确性。结果 穿刺病理结果显示腺癌 38例,鳞癌 30例,SCLC 10例。三组不同病理分型肺癌患者血清 NSE,SCC,CA125及血清 CYFRA21-1水平差异均有统计学意义( F=8.627,44.832,31.864,11.480,均 P<0.05)。受试者工作曲线( receiver operating characteristic,ROC)分析显示血清 CYFRA21-1和 CA125诊断肺腺癌的 AUC分别为 0.690和 0.691(95%CI=0.546~0.807,0.533~0.781,P<0.05)。ROC分析显示血清 CYFRA21-1,SCC及 CA125诊断鳞癌的 AUC分别为 0.681,0.675及 0.670(95%CI=0.561~0.801,0.557~0.794,0.550~0.791,P<0.05)。ROC分析显示血清 NSE,CYFRA21-1及 SCC诊断 SCLC的 AUC为 0.717,0.743及 0.699(95%CI=0.493~0.941,0.602~0.884,0.531~0.867, P<0.05)。血清 CYFRA21-1+CA125诊断肺腺癌的敏感度和特异度分别为 0.873和 0.756,血清 CYFRA21-1+SCC诊断肺鳞癌敏感度和特异度分别为 0.893和 0.822,血清 CYFRA21-1+SCC+CA125诊断肺鳞癌的敏感度和特异度分别为 0.915和 0.716。血清 NSE+CYFRA21-1诊断 SCLC的敏感度和特异度分别为 0.914和 0.786,血清 NSE+SCC+CYFRA21-1诊断 SCLC的敏感度和特异度分别为 0.920和 0.702。血清 CYFRA21-1+CA125,血清 CYFRA21-1+SCC及血清 CYFRA21-1+NSE对判断肺腺癌、肺鳞癌及 SCLC化疗疗效的 AUC分别为 0.822,0.804及 0.772(95%CI=0.708~0.936,0.697~0.911,0.641~0.903,均 P<0.05)。结论 不同病理类型肺癌患者血清 NSE,SCC,CA125及 CYFRA21-1水平表达各异,血清 NSE,SCC, CA125及 CYFRA21-1的检测有助于不同病理类型肺癌患者的诊断和化疗近期疗效的判断。

参考文献/References:

[1] 甄丽芳,凌敏.肺癌早期诊断现状与未来展望 [J].临床肺科杂志 ,2017,22(3):549-553. ZHEN Lifang.LING Min.Current status and future prospects of early diagnosis of lung cancer[J]. Journal of Clinical Pulmonary Medicine ,2017,22(3):549-553.
[2] GAO Wanlei, WANG Wentao, YAO Shihua, et al. Highly sensitive detection of multiple tumor markers for lung cancer using gold nanoparticle probes and microarrays[J]. Analytica Chimica Acta, 2017, 958: 77-84.
[3] 刘延梅,马少君,马庆,等.非小细胞肺癌患者组织 EGFR基因突变状况及预后分析 [J].现代检验医学杂志,2019, 34(1):22-25. LIU Yanmei, MA Shaojun, MA Qing, et al. Analysis of the status and outcome of epidermal growth factor receptor mutations in non-small cell lung cancer patients[J]. Journal of Modern Laboratory Medicine, 2019, 34(1):22-25.
[4] 张萍 , 王红义 , 杨迎桂 , 等 .血清 CEA, ProGRP, NSE和 CYFRA21-1联合检测在肺癌诊断中的应用研究 [J].现代检验医学杂志 , 2016, 31(2): 56-59. ZHANG Ping,WANG Hongyi,YANG Yinggui,et al. Clinical application of combined detection of CEA, ProGRP, NSE and CYFRA21-1 in diagnosis of lung cancer [J] .Journal of Modern Laboratory Medicine,,2016,31(2):56-59.
[5] AISNER D L. The revised college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline: A step forward for molecular cytopathology [J]. Archives of Pathology & Laboratory Medicine, 2018, 142(6): 684-685.
[6] 中华医学会 , 中华医学会肿瘤学分会 ,中华医学会杂志社 .中华医学会肺癌临床诊疗指南 (2018版 )[J].中华肿瘤杂志 ,2018,40(12):935-964. Chinese Medical Association,Oncology Society of Chinese Medical Association,Chinese Medical Association Publishing House. Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer ( Edition 2018) [J]Chinese Journal of Oncology,2018,40(12):935-964.
[7] GAO Li, XIE Sheng, LIU Hui, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema revisited with the 2015 World Health Organization classification of lung tumors[J]. The Clinical Respiratory Journal, 2018, 12(2): 652-658.
[8] KATAOKA Y, HIRANO K, NARABAYASHI T, et al. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study[J]. Cancer Chemotherapy and Pharmacology, 2018, 81(2): 333-337.
[9] 张仁锋,张岩,温丰标,等. 6 058例肺癌患者病理类型和临床流行病学特征的分析 [J].中国肺癌杂志 , 2016, 19(3):129-135. ZHANG Renfeng,ZHANG Yan,WEN Fengbiao,et al. Analysis of pathological types and clinical epidemiology of 6 058 patients with lung cancer [J]. Chinese Journal of Lung Cancer,2016,19(3):129-135.
[10] 陆舜,虞永峰,纪文翔. 2015年肺癌诊疗指南 :共识和争议 [J].解放军医学杂志, 2016, 41(1): 1-6. LU Shun,YU Yongfeng,JI Wenxiang. Guidelines for lung cancer in 2015: Consensus and controversy [J]. Medical Journal of Chinese People’s Liberation Army,2016,41(1):1-6.
[11] 尹志辉,周志伟,刘继勇,等.乳腺癌患者组织多项组化标记物与血清 CA153,CA125,CEA,25-OH-D3水平关联性分析模型建立及在预后判断的临床价值 [J].现代检验医学杂志 ,2019,34(3):47-54. YIN Zhihui,ZHOU Zhiwei,LIU Jiyong,et al. Establishment of a correlation analysis model between multi-group markers and serum CA153 ,CA125 ,CEA,25-OH-D3 in breast cancer patients and clinical value in prognosis[J] . Journal of Modern Laboratory Medicine ,2019,34(3):47-54.
[12] ABU HASSAAN S O. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125[J]. Danish Medical Journal, 2018, 65(4): 5463-5468.
[13] 熊娟.多种血清肿瘤标志物 (CY211,NSE,CEA,-CA125,CA199,SCC)对不同病理类型和临床分期肺癌的诊断价值 [J].中国社区医师 , 2017, 33(3):99-100. XIONG Juan. Diagnostic value of multiple serum tumor markers(CY211,NSE,CEA,CA125,CA199,S CC) in different pathological types and clinical stages of lung cancer[J]. Chinese Community Doctors, 2017, 33(3):99-100.
[14] 刘涛 , 杨燕 , 刘博 , 等 .联合检测胸腹腔积液 sCD44V6,CEA,CYFRA21-1,CA199,NSE,CA125对良恶性疾病鉴别诊断价值研究 [J].现代检验医学杂志, 2020, 35(2): 53-55, 64. LIU Tao,YANG Yan,LIU Bo,et al. Value of combined detection of sCD44V6, CEA, CYFRA21-1, CA199, NSE and CA125 in the differential diagnosis of benign and malignant pleural and peritoneal effusion [J].Journal of Modern Laboratory Medicine,2020,35(2):53-55,64.
[15] 王媛媛,刘婉,王萍,等.血清 CYFRA21-1,SCC-Ag,LDH联合检测对肺鳞癌与肺部感染鉴别诊断的价值初探 [J].现代肿瘤医学, 2018,26(13): 2033-2036. WANG Yuanyuan,LIU Wan,WANG Ping.et al. Com-bined detection value of serum CYFRA21-1,SCC-Ag and LDH levels in the differ-ential diagnosis of lung squamous cell carcinoma and pneumonia[J].Journal of Modern Oncology,2018,26(13):2033-2036.
[16] GADGEEL S, GOSS G, SORIA J C, et al. Evaluation of the VeriStrat. serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study[J]. Lung Cancer (Amsterdam, Netherlands), 2017, 109(11): 101-108.
[17] 赵车冬 , 闫玉珠 , 吴文婧 , 等 .血清 CEA,CYFRA21-1和 NSE水平在肺癌诊断与分型中的应用价值 [J].现代检验医学杂志 ,2016,31(6):59-61,65. ZHAO Chedong,YAN Yuzhu,WU Wenjing, et al. Appli-cation value of serum CEA,CYFRA2 1-1 and NSE lev-els in the diagnosis and typing of lung cancer[J]. Journal of Modern Laboratory Medicine,2016,31(6):59-61,65.
[18] 李东航 , 姚颐 , 耿庆 .中国临床肿瘤学会肺癌诊疗指南 (2018版 )更新解读 [J].临床外科杂志 , 2019, 27(1): 36-39. LI Donghang,YAO Yi, GENG Qing.Updated interpretation of Chinese society of clinical oncology guidelines for diagnosis and treatment of lung cancer (2018 Edition)[J].Journal of Clinical Surgery,2019,27(1):36-39.
[19] 郭九玲 ,扈成伟 ,李冬霞 ,等 .动态监测血清 CEA,CA19-9,CA125,CA153和 CYFRA21-1对肺癌患者围手术期疗效评估的临床研究 [J].癌症进展 , 2019, 17(14):1701-1703, 1725.

相似文献/References:

[1]张 萍a,王红义b,杨迎桂a,等.血清CEA,ProGRP,NSE和CYFRA21-1联合检测在肺癌诊断中的应用研究[J].现代检验医学杂志,2016,31(02):56.[doi:10.3969/j.issn.1671-7414.2016.02.017]
 ZHANG Pinga,WANG Hong-yib,YANG Ying-guia,et al.Clinical Application of Combined Detection of CEA,ProGRP,NSE and CYFRA21-1 in Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):56.[doi:10.3969/j.issn.1671-7414.2016.02.017]
[2]卢美红,鞠少卿,丛 辉,等.南通地区健康人群血清NSE电化学发光法检测参考区间的调查[J].现代检验医学杂志,2018,33(04):59.[doi:10.3969/j.issn.1671-7414.2018.04.015]
 LU Mei-hong,JU Shao-qing,CONG Hui,et al.Investigate of Serum NSE Reference Range of Healthy People in Nantong with Electrochemiluminescence[J].Journal of Modern Laboratory Medicine,2018,33(01):59.[doi:10.3969/j.issn.1671-7414.2018.04.015]
[3]彭 琦a,程少鹏b,陈辅萍a.非小细胞肺癌组织中NSE 的基因表达及与患者临床特征的相关性研究[J].现代检验医学杂志,2020,35(03):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
 PENG Qia,CHENG Shao-pengb,CHEN Fu-pinga.Correlation between NSE Gene Expression and Serum NSE Level in Tumor Tissues and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(01):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
[4]徐翠香,王建华,武 敏,等.胃癌患者血清CA724,NSE和 PGR水平联合检测对肿瘤临床病理分期及淋巴结转移的诊断价值[J].现代检验医学杂志,2021,36(01):6.[doi:10.3969/j.issn.1671-7414.2021.01.002]
 XU Cui-xiang,WANG Jian-hua,WU Min,et al.Diagnostic Value of Combined Detection of Serum CA724, NSE and PGR Levels in Patients with Gastric Cancer for Tumor Clinical Pathological Stage and Lymph Node Metastasis[J].Journal of Modern Laboratory Medicine,2021,36(01):6.[doi:10.3969/j.issn.1671-7414.2021.01.002]
[5]朱 娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
 ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(01):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[6]董旭才,李 斌,曹聪聪,等.临床实验室单标本气动传输系统改进对血清NSE 和Cyfra21-1 检测结果的影响及效果评价[J].现代检验医学杂志,2023,38(04):169.[doi:10.3969/j.issn.1671-7414.2023.04.031]
 DONG Xucai,LI Bin,CAO Congcong,et al.Effect and Evaluation of Single Specimen Pneumatic Transmission System Improvement on Serum NSE and Cyfra21-1 Detection in Clinical Laboratory[J].Journal of Modern Laboratory Medicine,2023,38(01):169.[doi:10.3969/j.issn.1671-7414.2023.04.031]

备注/Memo

备注/Memo:
作者简介:王妮娜(1985-),女,硕士,主治医师,研究方向:肿瘤的临床治疗与放疗, E-mail:baowangnin@163.com。通讯作者:崔翠花(1982-),女,硕士,主治医师,研究方向:肿瘤内科, E-mail:cch1212zj@163.com。
更新日期/Last Update: 2021-02-05